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Background/aim: To evaluate patients hospitalized in our clinic in the last 5 years with the diagnosis of intrahepatic cholestasis of
pregnancy (ICP).
Materials and methods: One hundred and fifty patients hospitalized with a diagnosis of ICP between January 2008 and May 2013 were
evaluated retrospectively and age, week at diagnosis, gestational age at delivery, period between diagnosis and delivery, fetal weight,
transaminases, and coagulation parameters were recorded. Patients were divided into groups according to their diagnosis weeks and
gravida. Accordingly, patients diagnosed before 32 weeks formed group A (n = 49) and those after 32 weeks formed group B (n = 101).
Data were evaluated with SPSS 16.0.
Results: There was a significant difference between group A and group B in terms of delivery period and fetal weights (P = 0.001, P =
0.035). Accordingly, the period between diagnosis and delivery and fetal weight were found to be longer and lower, respectively, in the
early-onset group. In terms of distribution of ICP according to time of diagnosis, patients were diagnosed mostly in the spring season
(60 cases, 40%) and in the month of March (27 cases, 18%).
Conclusion: According to our study, the birth weight of fetuses of patients with ICP diagnosed before 32 weeks are lower, although they
have the same gestational age at delivery as the fetuses of the patients with ICP diagnosed after 32 weeks.
Key words: Pregnancy, intrahepatic cholestasis of pregnancy, fetal weight

1. Introduction
Intrahepatic cholestasis of pregnancy (ICP) is a
pregnancy-specific liver disease that usually emerges in
the last trimester of pregnancy with generalized pruritus
of the skin and resolves itself spontaneously after birth.
Although it has a minimal risk for the mother, there are
serious risks for the fetus. It is diagnosed based on clinical
findings, elevation of serum bile acids, and increased liver
transaminases. There are differences in its prevalence in
different regions and countries. It is seen in the United
States, England, and Sweden at low rates such as 0.01%,
0.07%, and 2.8%, respectively, and in Chile and Bolivia
with the highest prevalence of 15% (1). It has been reported
that there has been a decrease in the prevalence of these
countries in recent years (2,3).
Although the exact etiology is unknown, it is
estimated that racial, genetic, hormonal, nutritional, and
environmental factors play a role (4). Itching and liver
function test abnormalities improve after birth completely.
One of the most sensitive tests in the diagnosis of ICP is
increase in total serum bile acids. It has been reported that
* Correspondence: iuyar03@yahoo.com

this increase was in parallel with an increase in fetal risks.
Fetal risks include preterm birth, low Apgar score, fetal
distress, sudden intrauterine fetal death, and meconiumstained amniotic fluid. Despite the use of various agents,
ursodeoxycholic acid (UDCA) is the most effective agent
in the treatment.
There is no standard method for the treatment and
follow-up for ICP. Close monitoring of these patients is
recommended in terms of both maternal and fetal risks. In
our study, we retrospectively evaluated pregnant women
who were treated at our hospital with the diagnosis of ICP
over the last 5 years.
2. Materials and methods
The study population was composed of 150 patients
hospitalized and treated in the last 5 years with the
diagnosis of ICP at our hospital. The patient files were
accessed by the ICD-10 computer recording system and
reviewed retrospectively. The study was approved by the
hospital ethics committee. The patients’ liver and biliary
tract imaging in terms of organic pathologies, hepatitis
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B and hepatitis C serology for viral hepatitis, coagulation
parameters, and complete blood count were recorded
in the form of case information. ICP usually arises in
the last trimester, and in particular in weeks 32 and 33
(5). We divided the patients with a diagnosis of ICP into
two groups according to weeks at diagnosis. Early-onset
(before 32 weeks) patients formed group A (n = 49) and
late-onset (after 32 weeks) patients formed group B (n =
101). In addition, patients were divided into two groups
according to the number of pregnancies. The patients
with gravida one formed group I (n = 63), and those with
gravida two or more formed group II (n = 87). These groups
were compared in terms of age, gravida, transaminases,
coagulation parameters, complete blood count, cholestasis
diagnostic weeks, period between diagnosis and delivery,
gestational weeks, and fetal weight.
The data were analyzed using SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA). Student’s t-test and the chi-square test
were used to compare the groups. P < 0.05 was considered
significant.

3. Results
The mean age, mean gravida, and mean week of diagnosis
of the 150 patients diagnosed with ICP were 28.1 ± 6.2
years, 2.2 ± 1.6, and 31.5 ± 5.8 weeks, respectively. The
mean gestational age at delivery, mean time passing until
delivery, and mean birth weight were 36.7 ± 2.0 weeks,
4.8 ± 6.3 weeks, and 3070.0 ± 533.9 g, respectively. The
laboratory tests averages were: alkaline phosphatase, 217.9
± 87.0 IU; aspartate aminotransferase, 97.6 ± 71.8 IU;
alanine aminotransferase, 158.6 ± 137.9 IU; prothrombin
time, 12.9 ± 3.3 s; international normalized ratio, 1.00 ±
0.32; partial thromboplastin time, 29.1 ± 4.6 s, white blood
cell count, 10,204 ± 2489.8, hemoglobin, 11.8 ± 1.3 g/dL,
hematocrit, 35.2 ± 3.7%, and platelet count, 236.6 ± 75.5
(Table 1).
The numbers of deliveries before the 37th pregnancy
week (premature) and after the 37th weeks were 52 (34.6%)
and 98 (65.3%), respectively. Cases of vaginal delivery
and cesarean section were 37 (24.6%) and 113 (75.3%),

Table 1. Demographic, clinical, and laboratory findings of the patients.
Mean ± SD

Min–max

Age (years)

28.1 ± 6.2

17–46

Gravida

2.2 ± 1.6

1–9

Gestational week at diagnosis

31.5 ± 5.8

11–39

Gestational week at delivery

36.7 ± 2.0

28–40

Period passing until delivery (weeks)

4.8 ± 6.3

0–35

Fetal weight (g)

3070.0 ± 533.9

1650–4480

ALP

217.9 ± 87.0

23–662

AST

97.6 ± 71.8

16–337

ALT

158.6 ± 137.9

13–652

PT

12.9 ± 3.3

10.7–45.3

INR

1.00 ± 0.32

0.74–3.36

PTT

29.1 ± 4.6

16.1–50.2

WBC

10,204 ± 2489.8

5600–18,600

HB

11.8 ± 1.3

8.2–15.0

HCT

35.2 ± 3.7

24.2–44.8

PLT

236.6 ± 75.5

94–544

T.BIL

0.89 ± 0.34

0.2–2.1

ALP: Alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase,
PT: prothrombin time, INR: international normalized ratio, PTT: partial thromboplastin time,
WBC: white blood cell count, HB: hemoglobin, HTC: hematocrit, PLT: platelet count, T.BIL:
total bilirubin.
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respectively. There were 6 cases of twin pregnancy (4%),
and 1 case (0.6%) of IVF pregnancy.
The mean ages of group I and group II were 24.8
± 5.1 and 30.5 ± 5.8 years, respectively and there was a
significant difference between the two groups in terms of
the mean age (P = 0.001). Accordingly, patients in group I
were younger. There was no significant difference between
the two groups in terms of cholestasis diagnosis week,
gestational weeks at delivery, period passing until the
delivery, fetal weight, alkaline phosphatase, transaminases,
or complete blood count and coagulation tests (Table 2).
The mean gestational week at diagnosis in group A
and group B was 26.07 ± 6.9 and 34.72 ± 2.0 respectively.
In group A (early-onset, before 32 weeks) and group B
(late-onset, after 32 weeks) the mean periods passing until
delivery were 10.1 ± 7.5 and 2.4 ± 3.8 weeks, respectively,
and the mean fetal weights were 2924.3 ± 574.5 g and
3135.6 ± 504.1 g, respectively. There was a significant
difference between the two groups in terms of the period
passing until delivery and fetal weights (P = 0.001, P
= 0.035). The gestational weeks at delivery were 36.3 ±
2.6 and 36.8 ± 1.6 weeks, respectively, and there was no
difference in this respect between the two groups (P =

0.166). Accordingly, although mean weeks at delivery was
the same in both groups, the period passing until delivery
was longer in Group A and fetal weights were lower. There
was no significant difference between the two groups in
terms of age, alkaline phosphatase, transaminases, or
complete blood count and coagulation tests (Table 3).
When the distribution of the months in which the
patients were diagnosed was examined, the most common
month was March with 27 (18%) patients, and April was
the second most common month, with 21 (14%) patients.
When the distribution according to the seasons was
examined, spring was the most common season in which
the patients were diagnosed, with 60 (40%) patients, and
the second season was winter, with 44 (29.3%) patients.
4. Discussion
ICP is a liver disease that is the most common cause of
jaundice in pregnant women after viral hepatitis. It has
been reported that there are serious fetal risks and minimal
maternal risks. Despite the maternal risks being minimal,
it has been stated that these patients have a predisposition
to certain other diseases. In a study conducted recently on
the examination of the diseases diagnosed over long-term

Table 2. Comparison of group I and group II.
Group I (n = 63)

Group II (n = 87)

P-value

Age (years)

24.8 ± 5.1

30.5 ± 5.8

0.001

Gestational week at diagnosis

31.6 ± 6.1

32.1 ± 5.6

0.614

Gestational week at delivery

36.4 ± 2.1

36.8 ± 1.8

0.279

Period passing until delivery (weeks)

5.0 ± 6.7

4.7 ± 6.0

0.791

Fetal weight (g)

3043.3 ± 476.8

3089.6 ± 574.6

0.625

ALP

213.2 ± 71.0

221.3 ± 97.2

0.575

AST

87.9 ± 68.4

104.7 ± 73.8

0.157

ALT

144.4 ± 131.9

168.9 ± 141.9

0.284

PT

13.2 ± 5.0

12.8 ± 1.2

0.566

INR

1.06 ± 0.52

0.97 ± 0,10

0.322

PTT

29.3 ± 5.1

28.9 ± 4.1

0.691

WBC

10,504 ± 2358.4

9919.5 ± 2569.0

0.179

HB

11.9 ± 1.3

11,8 ± 1.3

0.737

HCT

35.2 ± 4.0

35.1 ± 3.6

0.861

PLT

236.6 ± 77.3

236.6 ± 74.6

0.999

Values are mean ± SD.
ALP: Alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, PT: prothrombin
time, INR: international normalized ratio, PTT: partial thromboplastin time, WBC: white blood cell count,
HB: hemoglobin, HTC: hematocrit, PLT: platelet count.
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Table 3. Comparison of group A (n = 49, <32 weeks) and group B (n = 101, ≥32 weeks).
Group A

Group B

P-value

Age (years)

27.04 ± 6.1

28.4 ± 6.1

0.209

Gestational weeks at delivery

36.3 ± 2.6

36.8 ± 1.6

0.166

Period passing until delivery (weeks)

10.1 ± 7.5

2.4 ± 3.8

0.001

Fetal weight (g)

2924.3 ± 574.5

3135.6 ± 504.1

0.035

ALP

216.1 ± 88.9

223.2 ± 88.1

0.657

AST

101.6 ±76.1

95.8 ± 72.2

0.664

ALT

172.4 ± 143.8

151.5 ± 137.7

0.410

PT

12.6 ± 1.0

13.2 ± 4.2

0.366

INR

0.94 ± 0.08

1.03 ± 0.39

0.401

PTT

29.7 ± 5.2

28.8 ± 4.3

0.369

WBC

9577 ± 1848

10,366 ± 2784

0.087

HB

11.9 ± 1.2

11.8 ± 1.3

0.453

HCT

35.3 ± 3.5

35.1 ± 3.8

0.800

PLT

241.9 ± 76.4

236.0 ± 76.1

0.671

Values are mean ± SD.
ALP: Alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, PT: prothrombin
time, INR: international normalized ratio, PTT: partial thromboplastin time, WBC: white blood cell count,
HB: hemoglobin, HTC: hematocrit, PLT: platelet count.

periods in patients with cholestasis, hepatobiliary diseases,
breast cancer, and hypothyroidism were more common
and hypertension, cholesterolosis, and cardiac arrhythmia
were seen to a lesser degree in these patients (6).
When the week of diagnosis of the patients was
evaluated, despite the fact that there were patients who
were diagnosed during the first trimester, in general, they
were diagnosed with ICP at average of the third trimester,
consistent with the literature. In the study conducted by
Kenyon et al. on 70 patients with cholestasis, the initiation
of itching, week of diagnosis, cesarean rate, and delivery
rate before the 37th week were found to be 30 weeks, 33.7
weeks, 36%, and 17%, respectively, while there was no
intrauterine fetal loss and 14% of infants were sent to the
neonatal intensive care unit after birth (5). In our study,
diagnosis of ICP was performed at a mean of 31.5 weeks,
and the delivery rate before the 37th week and the cesarean
rate were 34.6% and 75.3%, respectively. According to
our evaluation, the increase in cesarean rate is due to the
patients undergoing repeated cesarean sections. In parallel
with our study, the preterm delivery rate has been reported
as 36%–38 % in the literature (7,8).
Increase in maternal serum bile acids is a significant
predictor. There is a correlation between serum bile acids
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and perinatal outcomes. It has been reported that when
maternal serum levels were under 40 µmol/L, perinatal
outcomes were good, and when they were above 40
µmol/L, the incidence of intrauterine mortality increased
(9,10). Sudden intrauterine fetal loss rates in ICP were
reported to be 7%, and 90% of these losses happened after
the 37th gestational week (11). In our study, the low rate of
fetal loss of 1/150 (0.6%) can be related with mean delivery
week of our patients being 36.7 weeks. UDCA is started as
a routine in our hospital for the patients with the diagnosis
of ICP. UDCA is selected as the first choice due to its
improvement of the maternal symptoms, acceleration of
bile transport from placental trophoblasts, and the absence
of a negative impact on the mother and fetus. Although
it is highly effective in healing the maternal symptoms
and reducing the transaminases, the positive impact on
the results of fetal healing is not clear. It was reported in
the metaanalysis of nine randomized controlled trials
conducted recently that UDCA reduced preterm birth,
fetal distress, respiratory distress syndrome, and the need
for neonatal care (12). Because no other treatment was
received other than UDCA, the low fetal loss rate in our
study is controversial as it is difficult to discern whether it
was caused by UDCA treatment or not.
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Many factors are culpable in the etiology of ICP. At a
basic level, there are genetic, hormonal, nutritional, and
environmental factors. It has been determined that ICP
showed seasonal changes, and this was seen especially
during the winter months. The reason for this was failure
to obtain sufficient diet and selenium during the winter
(13). Selenium plays a role in the detoxification of the liver
as a cofactor of glutathione peroxidase, and bile secretion
and formation are impaired in the event of its deficiency
(14,15). In our study, when the time of diagnosis of ICP
is examined, it is noteworthy that the spring and winter
seasons are the most common seasons. Estrogen and
progesterone have been considered among hormonal
factors. The findings such as emergence in the second and
third trimesters, being more common in twin pregnancies,
spontaneous disappearance after birth, and reemergence
of cholestasis with oral contraceptives in patients who had
ICP support the possibility that hormonal mechanisms
play an important role in the etiology (16). It is known that,
although there was no difference with normal pregnancies
in terms of high estrogen and progesterone, metabolites in
the liver impair the expression of the canalicular protein
providing transport of bile acids in patients genetically
predisposed (17,18). We found that the twin and IVF
pregnancy rate was 4% and 0.6%, respectively. Twin
pregnancy and IVF pregnancy have been reported as
20%–22% and 2.7%, respectively, in the literature (19–21).
In our study, we evaluated patients separated into two
groups as primigravid and multigravid. Our aim here was
to determine the effect of first exposure to high estrogen
and progesterone metabolites on the course of ICP. There
was no significant difference between primigravid and
multigravid patients in terms of diagnosis week of ICP,
period passing until delivery, gestational age at delivery,

fetal weights, transaminases, and coagulation parameters.
We determined that fetal weights were lower in
early-onset ICP than late-onset ICP, although there was
no difference between the two groups in terms of the
mean gestational weeks at delivery. Taking into account
that there was no significant difference in terms of age,
hematocrit, transaminases, and coagulation parameters
between the two groups, further studies should be done
for the cause of the difference between the fetal weights.
On the other hand, the period passing until delivery was
longer in early-onset group. Because of waiting until the
37th gestational week in order to proceed with labor, it is
an expected result that the period passing until delivery in
early-onset ICP is longer.
When we evaluated ICP in terms of intrauterine fetal
death, intrauterine fetal death rates were relatively high at
15% in old studies and 3.5% in more recent studies (22).
In a study conducted by Turunen et al., intrauterine fetal
death rate was found to be 1.2%, and in our study, it was
found to be 0.6%. In the same study, ICP increased the
rates of induction of delivery and cesarean section. In our
study, the rate of cesarean section was 75.3% (6). When
it is taken into account that ICP is not an indication for
cesarean section alone, we can further say that this increase
is mostly due to the cases of repeated cesareans.
In conclusion, according to our study, the fetuses of
patients with ICP diagnosed at under 32 weeks have lower
birth weights although they have the same gestational age
as the fetuses of the patients with ICP diagnosed after 32
weeks, and ICP is encountered mostly in the spring season.
Among primigravid and multigravid patients, there is
no difference in terms of week of diagnosis, gestational
week at delivery, fetal weights, complete blood count,
transaminase levels, and coagulation parameters.

References
1.

Abedin P, Weaver J, Egginton E. Intrahepatic cholestasis of
pregnancy: prevalence and ethnic distribution. Ethn Health
1999; 4: 35–37.

6.

Turunen K, Sumanen M, Haukilahti RL, Kirkinen P, Mattila
K. Good pregnancy outcome despite intrahepatic cholestasis.
Scand J Prim Health Care 2010; 28: 102–107.

2.

Reyes H. Sex hormones and bile acids in intrahepatic
cholestasis of pregnancy. Hepatology 2008; 47: 376–379.

7.

Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet
Gynecol Clin North Am 2010; 37: 269–282.

3.

Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic
cholestasis of pregnancy: molecular pathogenesis, diagnosis
and management. J Hepatol 2000; 33: 1012–1021.

8.

4.

Diken Z, Usta IM, Nassar AH. A Clinical approach to
intrahepatic cholestasis of pregnancy. Am J Perinatol 2014; 31:
1–8.

Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, Moshkov
AV, Xie Q, Keitel V, Nikolaev VO, Williamson C, Gorelik J.
Bile acid induced arrhythmia is mediated by muscarinic M2
receptors in neonatal rat cardiomyocytes. PLoS One 2010; 15:
5 e9689.

9.

Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi
M, Pathak B, Goodwin TM. Pregnancy outcomes during an
era of aggressive management for intrahepatic cholestasis of
pregnancy. Am J Perinatol 2008; 25: 341–334.

5.

Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM,
Shennan AH. Obstetric cholestasis, outcome with active
management: a series of 70 cases. BJOG 2002; 109: 282–288.

727

UYAR et al. / Turk J Med Sci
10.

Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis
of pregnancy: relationships between bile acid levels and fetal
complication rates. Hepatology 2004; 40: 467–474.

11.

Williamson C, Hems LM, Goulis DG, Walker I, Chambers J,
Donaldson O, Swiet M, Johnston DG. Clinical outcome in a
series of cases of obstetric cholestasis identified via a patient
support group. BJOG 2004; 111: 676–681.

12.

Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J,
Binder T, Nicastri PL, Locatelli A, Floreani A, Hernandez I
et al. Efficacy of ursodeoxycholic acid in treating intrahepatic
cholestasis of pregnancy: a meta-analysis. Gastroenterology
2012; 143: 1492–1501.

13.

Brites D, Rodrigues CM, van-Zeller H, Brito A, Silva R.
Relevance of serum bile acid profile in the diagnosis of
intrahepatic cholestasis of pregnancy in an high incidence area:
Portugal. Eur J Obstet Gynecol Reprod Biol 1998; 80: 31–38.

14.

Reyes H, Báez ME, González MC, Hernández I, Palma J,
Ribalta J, Sandoval L, Zapata R. Selenium, zinc and copper
plasma levels in intrahepatic cholestasis of pregnancy, in
normal pregnancies and in healthy individuals, in Chile. J
Hepatol 2000; 32: 542–554.

15.

Kauppila A, Korpela H, Mäkilä UM, Yrjänheikki E. Low serum
selenium concentration and glutathione peroxidase activity in
intrahepatic cholestasis of pregnancy. Br Med J (Clin Res Ed)
1987; 294: 150–152.

16.

Schreiber A, Simon F. Estrogen induced cholestasis: clues to
pathogenesis and treatment. Hepatology 1983; 3: 607–613.

728

17.

Meng LJ, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta
J, Sjovall J. Progesterone metabolites and bile acids in serum
of patients with intrahepatic cholestasis of pregnancy: effect
of ursodeoxycholic acid therapy. Hepatology 1997; 26: 1553–
1579.

18.

Simon FR, Fortune J, Iwahashi M, Gartung C, Wolkoff A,
Sutherland E. Ethinyl estradiol cholestasis involves alterations
in expression of liver sinusoidal transporters. Am J Physiol
1996; 271: 1043–1052.

19.

Gonzales MC, Reyes H, Arrese M, Figueroa D, Lorca B,
Andresen M, Segovia N, Molina C, Arce S. Intrahepatic
cholestasis of pregnancy in twin pregnancies. J Hepatol 1989;
9: 84–90.

20.

Rioseco AJ, Ivankovic MB, Manzur A, Hamed F, Kato SR,
Parer JT, Germain AM. Intrahepatic cholestasis of pregnancy:
a retrospective case-control study of perinatal outcome. Am J
Obstet Gynecol 1994; 170: 890–895.

21.

Koivurova S, Hartikainen AL, Karinen L, Gissler M, Hemminki
E, Martikeinen, Tuomivaara L, Jarvelin MR . The course of
pregnancy and delivery and the use of maternal healthcare
services after standard IVF in Northern Finland 1990-1995.
Hum Reprod 2002; 17: 2897–2903.

22.

Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy.
World J Gastroenterol 2009; 15: 2049–2066.

